NCT01660568已完成不适用
Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Overall response rate
研究概览
简要总结
We retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •NK/T cell lymphoma
- •relapse or refractory disease
- •gemcitabine containing treatment
排除标准
- 未提供
结局指标
主要结局
Overall response rate
时间窗: 2012-May
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeT-lymphoblastic LymphomaNCT06376721Beijing Tongren Hospital43
Unknown
2 期
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell LymphomaLymphoma, Extranodal NK-T-CellNCT03154918Sichuan University60
Unknown
1 期
Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKINon-small Cell Lung CancerNCT02066870Betta Pharmaceuticals Co., Ltd.9
已完成
2 期
The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung CancerTHE Efficacy and Safety of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung CancerNCT01797913Fudan University70
已完成
不适用
Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell LymphomaNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeNCT05058755Xinhua Hospital, Shanghai Jiao Tong University School of Medicine62